Effects of a Public Subsidy Program for Mumps Vaccine on Reducing the Disease Burden in Nagoya City, Japan

被引:8
作者
Ozaki, Takao [1 ]
Goto, Yasuhiro [2 ]
Nishimura, Naoko [1 ]
Nakano, Takashi [3 ]
Kumihashi, Hideaki [4 ]
Kano, Munehide [4 ]
Ohfuji, Satoko [5 ,6 ]
机构
[1] Konan Kosei Hosp, Dept Pediat, 137 Ohmatsubara,Takaya Cho, Konan, Aichi 4838704, Japan
[2] Kamiiida Daiichi Gen Hosp, Dept Pediat, Nagoya, Aichi 4620802, Japan
[3] Kawasaki Med Sch, Dept Pediat, Okayama 7010192, Japan
[4] Takeda Pharmaceut Co Ltd, Global Vaccine Business Unit, Tokyo 1038668, Japan
[5] Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Osaka 5458585, Japan
[6] Osaka City Univ, Grad Sch Med, Res Ctr Infect Dis Sci, Osaka 5458585, Japan
关键词
D O I
10.7883/yoken.JJID.2018.276
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Nagoya City initiated a public subsidy program for mumps vaccination using either the Torii or Hoshino strains in August 2010. To determine the effects of the program, we used publicly available information from Nagoya City to investigate the changes in immunization rates and numbers of patients who developed post-immunization adverse reactions, including post-vaccinal aseptic meningitis, in the 7 years since its initiation. We also investigated the numbers of mumps patients reported by sentinel sites in a national database during this period. The immunization rate in one-year-old children increased from 24.3% before the program to 91.0% after 7 years. The mean numbers of reported mumps cases per sentinel site in one-year-old to preschool children the age groups targeted by the program were 12.9 in the 7 years before the program and 4.93 in the 7 years after initiation of the program, showing a significant decrease of 1/2.6 (p = 0.01). The number of vaccinations during the 6.5-year period was 140,316, with only one case of aseptic meningitis reported (0.7 cases/100,000 vaccinations). No other serious adverse reactions were observed. The present findings demonstrate that the public subsidy program in Nagoya City is an effective and safe measure against mumps in children.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2017, INDIVIDUAL NOTIFICAT
[2]  
[Anonymous], 2015, REPORT POSTVACCINAL, V156
[3]  
Ihara T, 2013, CLIN STUDY EFFICACY, P19
[4]  
Ihara T, 2010, RINSHO UIRUSU, V38, P386
[5]  
Kawaguchi M, 2017, J PEDIAT INFECT DIS, V29, P227
[6]  
Kitasato Daiichi Sankyo Vaccine Co. Ltd, PACK INS FREEZ DRIED
[7]  
Korematsu S, 2012, J JPN PEDIAT SOC, V116, P1380
[8]  
Maruyama H, 1994, CLIN VIROL, V22, P77
[9]  
Ministry of Health Labour and Welfare and National Institute of Infectious Diseases, TABL NUMB REP CAS NA
[10]  
Ministry of Health Labour and Welfare of Japan, 2017, 31 SUBC M ADV REACT